MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

8300	Companies
115014	Keywords
55394	Articles
62493	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 08/26/2024 at 14:00, 2 months 26 days ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
A pre-clinical study highlights Ketamir-2's superiority over oral ketamine in normalizing pain thresholds, showing promise for neuropathic pain treatment

MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pre-clinical Study Pain Thresholds
BRIEF

published on 08/19/2024 at 13:35, 3 months 2 days ago

MIRA Pharmaceuticals annonce la phase finale avant la soumission de l'IND

MIRA-55 Ketamir-2 Traitements Neurologiques Soumission De L'IND Progrès De La Réglementation
BRIEF

published on 08/19/2024 at 13:35, 3 months 2 days ago

MIRA Pharmaceuticals Announces Final Phase Before IND Submission

Neurological Treatments MIRA-55 Ketamir-2 IND Submission Regulatory Progress
PRESS RELEASE

published on 08/19/2024 at 13:30, 3 months 2 days ago

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
MIRA Pharmaceuticals, a leading pre-clinical-stage company, provides an update on its achievements and scientific advancements, nearing a milestone: IND application submission for Ketamir-2 and regulatory progress for MIRA-55

IND Application Scientific Advancements MIRA Pharmaceuticals Regulatory Progress Pre-clinical-stage
BRIEF

published on 08/12/2024 at 14:05, 3 months 9 days ago

MIRA Pharmaceuticals Unveils Promising Metabolite Nor-Ketamir-2

Neurological Treatments Preclinical Data Bioavailability Ketamir-2 Nor-Ketamir-2
BRIEF

published on 08/12/2024 at 14:05, 3 months 9 days ago

MIRA Pharmaceuticals dévoile un métabolite prometteur, le Nor-Ketamir-2

Biodisponibilité Ketamir-2 Nor-Ketamir-2 Traitements Neurologiques Données Précliniques
PRESS RELEASE

published on 08/12/2024 at 14:00, 3 months 9 days ago

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
MIRA Pharmaceuticals unveils new preclinical data on innovative drug candidate Ketamir-2's metabolite Nor-Ketamir-2, showcasing enhanced bioavailability and formulation for advanced at-home neurological treatments

Neurological Treatments Preclinical Data Bioavailability MIRA Pharmaceuticals Ketamir-2
BRIEF

published on 07/25/2024 at 13:05, 3 months 27 days ago

MIRA Pharmaceuticals dévoile des données de liaison sélectives NMDA pour Ketamir-2

Approbation De La FDA Analogue De Kétamine Récepteur NMDA Effets Secondaires Toxicologie
BRIEF

published on 07/25/2024 at 13:05, 3 months 27 days ago

MIRA Pharmaceuticals Unveils Selective NMDA Binding Data for Ketamir-2

FDA Approval Ketamine Analog NMDA Receptor Side Effects Toxicology
PRESS RELEASE

published on 07/25/2024 at 13:00, 3 months 27 days ago

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action
MIRA Pharmaceuticals announced positive preclinical data for novel ketamine analog Ketamir-2, showing selective NMDA inhibition and enhanced safety profile, advancing towards potential IND submission

Preclinical Data Neurological Disorders MIRA Pharmaceuticals Ketamir-2 IND Submission

Accesswire

Published on 11/21/2024 at 15:30, 31 minutes ago

CLS Health Opens New Comprehensive Care Clinic in Sugar Creek
Published on 11/21/2024 at 15:05, 56 minutes ago

"The Not-So-Secret Lives of REAL 'Mormon' Wives" - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/21/2024 at 15:00, 1 hour 1 minute ago

2-10 Home Buyers Warranty Makes Triumphant Entry Into Oklahoma Market
Published on 11/21/2024 at 15:00, 1 hour 1 minute ago

Sound Physicians’ ACO Achieves $22.9M Total Savings in 2023 Medicare Shared Savings Program
Published on 11/21/2024 at 15:00, 1 hour 1 minute ago

BlackBerry AtHoc "In Process" Finalization for FedRAMP High Authorization

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 15:41, 19 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 37 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 38 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 39 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 15:20, 40 minutes ago

Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc

Les Echos

Published on 11/21/2024 at 06:58, 9 hours 3 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 3 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 3 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 19 hours 54 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 20 hours 41 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE